Novo Nordisk’s Pipeline Verdict Looms as Wegovy’s Formulary Edge Crumbles and Buybacks Fall Shor
As commercial pressures mount from Lilly rivals and patent expiries, Novo Nordisk’s upcoming data readouts for CagriSema and…
Browsing Tag